🔴 UroGen Pharma is trading 17.93% down after Q3 loss and reduced full-year guidance

UroGen Pharma is trading at $28.08, down 17.93% on November 4, 2026, after third-quarter results missed estimates and full-year guidance was reduced.

• The company reported a $0.03 loss per share, missing estimates, and $89 million in revenue, slightly below expectations.
• ZUSDURI sales beat estimates at $68 million, while JELMYTO revenue declined year over year.
• Full-year guidance was reduced to approximately $90 million from $97–$101 million.